Neurocrine Biosciences Inc (NAS:NBIX)
$ 126.59 -1.32 (-1.03%) Market Cap: 12.82 Bil Enterprise Value: 11.84 Bil PE Ratio: 33.94 PB Ratio: 4.71 GF Score: 85/100

Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 01:40PM GMT
Release Date Price: $113.16 (-4.38%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. We will continue with the next session. Good morning, everyone. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. I'm very pleased to host in our next session Neurocrine Biosciences. Joining us from management is Kevin Gorman, the CEO; and we are also pleased to have Eiry Roberts, the Chief Medical Officer, with us here as well from the West Coast. It's early there. So we certainly appreciate both of you joining us here for our morning session.

As with the prior sessions here at the Goldman Sachs conference, I'll kick it off with some introductory remarks, and then I'll turn it over to Kevin, after which we'll go into the Q&A session. If along the way, if any clients or investors have questions for Neurocrine, please feel free to submit them through the Goldman Sachs Research portal, and time permitting at the end, we'll read 1 or 2 questions and we'll let the company respond to them. Alternatively, you can e-mail the questions to me directly. And again, if we have a minute or 2 at the end,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot